|
1
|
Ferlay J, Shin HR, Bray F, et al:
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int
J Cancer. 127:2893–2917. 2010.
|
|
2
|
Yeh CT, Liang KH, Lin CC, Chang ML, Hsu CL
and Hung CF: A single nucleotide polymorphism on the GALNT14 gene
as an effective predictor of response to chemotherapy in advanced
hepatocellular carcinoma. Int J Cancer. 134:1214–1224. 2014.
|
|
3
|
Perz JF, Armstrong GL, Farrington LA, et
al: The contributions of hepatitis B virus and hepatitis C virus
infections to cirrhosis and primary liver cancer worldwide. J
Hepatol. 45:529–538. 2006.
|
|
4
|
Liang KH, Lin CC and Yeh CT: GALNT14 SNP
as a potential predictor of response to combination chemotherapy
using 5-FU, mitoxantrone and cisplatin in advanced HCC.
Pharmacogenomics. 12:1061–1073. 2011.
|
|
5
|
Venook AP, Papandreou C, Furuse J and de
Guevara LL: The incidence and epidemiology of hepatocellular
carcinoma: a global and regional perspective. Oncologist. 15(Suppl
4): 5–13. 2010.
|
|
6
|
Roberts RJ: How restriction enzymes became
the workhorses of molecular biology. Proc Natl Acad Sci USA.
102:5905–5908. 2005.
|
|
7
|
Botstein D, White RL, Skolnick M and Davis
RW: Construction of a genetic linkage map in man using restriction
fragment length polymorphisms. Am J Hum Genet. 32:314–331.
1980.
|
|
8
|
Rommens JM, Iannuzzi MC, Kerem B, et al:
Identification of the cystic fibrosis gene: chromosome walking and
jumping. Science. 245:1059–1065. 1989.
|
|
9
|
Collins FS: Positional cloning: let’s not
call it reverse anymore. Nat Genet. 1:3–6. 1992.
|
|
10
|
Saiki RK, Scharf S, Faloona F, et al:
Enzymatic amplification of beta-globin genomic sequences and
restriction site analysis for diagnosis of sickle cell anemia.
Science. 230:1350–1354. 1985.
|
|
11
|
Kwok PY: SNP genotyping with fluorescence
polarization detection. Hum Mutat. 19:315–323. 2002.
|
|
12
|
Liang KH, Fen JJ, Chang HH, Wang HW and
Hwang Y: A base-calling algorithm for Tm-shifted melting curve SNP
assay. J Clin Bioinforma. 1:32011.
|
|
13
|
International HapMap 3 Consortium.
Altshuler DM, Gibbs RA, Peltonen L, et al: Integrating common and
rare genetic variation in diverse human populations. Nature.
467:52–58. 2010.
|
|
14
|
Wellcome Trust Case Control Consortium.
Genome-wide association study of 14,000 cases of seven common
diseases and 3,000 shared controls. Nature. 447:661–678. 2007.
|
|
15
|
Bauer CH, Vischer P, Grünholz H and
Reutter W: Glycosyltransferases and glycosidases in Morris
hepatomas. Cancer Res. 37:1513–1518. 1977.
|
|
16
|
Mandel U, Hassan H, Therkildsen MH,
Rygaard J, Jakobsen MH, Juhl BR, Dabelsteen E and Clausen H:
Expression of polypeptide GalNAc-transferases in stratified
epithelia and squamous cell carcinomas: immunohistological
evaluation using monoclonal antibodies to three members of the
GalNAc-transferase family. Glycobiology. 9:43–52. 1999.
|
|
17
|
Kohsaki T, Nishimori I, Nakayama H,
Miyazaki E, Enzan H, Nomoto M, Hollingsworth MA and Onishi S:
Expression of UDP-GalNAc: polypeptide
N-acetylgalactosaminyltransferase isozymes T1 and T2 in human
colorectal cancer. J Gastroenterol. 35:840–848. 2000.
|
|
18
|
Wu YM, Liu CH, Hu RH, Huang MJ, Lee JJ,
Chen CH, Huang J, Lai HS, Lee PH, Hsu WM, Huang HC and Huang MC:
Mucin glycosylating enzyme GALNT2 regulates the malignant character
of hepatocellular carcinoma by modifying the EGF receptor. Cancer
Res. 71:7270–7279. 2011.
|
|
19
|
Park JH, Nishidate T, Kijima K, Ohashi T,
Takegawa K, Fujikane T, Hirata K, Nakamura Y and Katagiri T:
Critical roles of mucin 1 glycosylation by transactivated
polypeptide N-acetylgalactosaminyltransferase 6 in mammary
carcinogenesis. Cancer Res. 70:2759–2769. 2010.
|
|
20
|
Wagner KW, Punnoose EA, Januario T, et al:
Death-receptor O-glycosylation controls tumor-cell sensitivity to
the proapoptotic ligand Apo2L/TRAIL. Nat Med. 13:1070–1077.
2007.
|
|
21
|
Thorburn A, Behbakht K and Ford H: TRAIL
receptor-targeted therapeutics: resistance mechanisms and
strategies to avoid them. Drug Resist Updat. 11:17–24. 2008.
|
|
22
|
Wu C, Guo X, Wang W, et al:
N-Acetylgalactosaminyltransferase-14 as a potential biomarker for
breast cancer by immunohistochemistry. BMC Cancer. 10:1232010.
|
|
23
|
Obi S, Yoshida H, Toune R, Unuma T, Kanda
M, Sato S, Tateishi R, Teratani T, Shiina S and Omata M:
Combination therapy of intraarterial 5-fluorouracil and systemic
interferon-alpha for advanced hepatocellular carcinoma with portal
venous invasion. Cancer. 106:1990–1997. 2006.
|
